Frequent urination

KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Clinical medicine, Medicine, Urology, Urinary incontinence, Overactive bladder, Urine, Nocturia, Urinary urgency, Frequent urination, Urinary bladder, Urination

Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

Key Points: 
  • Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.
  • Overactive bladder (OAB) is the name for a group of urinary symptoms characterized by urinary urgency, usually accompanied by increased daytime frequent urination and/or nocturia, and in some cases by urge urinary incontinence.
  • KYORIN has been making a contribution to improving the quality of life of patients with OAB through early penetration of the agent into the Japanese market.
  • With the execution of this agreement, KYORIN will now work with Eisai to make the agent available in the licensed territory and promote the expansion of its business internationally.

Global $11.6 Billion Urinary Tract Infection Treatment Market to 2027

Retrieved on: 
Thursday, February 11, 2021
Urinary tract infection, Frequent urination

DUBLIN, Feb. 11, 2021 /PRNewswire/ -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 11, 2021 /PRNewswire/ -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics.
  • R& D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market.
  • Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period.

Urinary Tract Infection Treatment Markets, 2027 - COVID-19 Impact and Global Analysis by Drug Class, Indication, Distribution Channel, and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, February 8, 2021
Health, Pharmaceutical, Medical specialties, Medicine, Urinary tract infection, Clinical medicine, Frequent urination, Nitrite test

The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics.
  • R&D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market.
  • Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period.